Galectin Therapeutics Inc.

Hepatology and Portal Hypertension

Research activity is centered on esophageal varices in the setting of nonalcoholic steatohepatitis (NASH)–related cirrhosis, with attention to complications linked to advanced liver disease and increased portal pressure.

  • Esophageal varices
  • NASH cirrhosis
  • Portal hypertension

The sponsor’s clinical research is focused on preventing variceal development in patients with cirrhosis associated with metabolic liver injury.

Fibrosis and Chronic Liver Complications

The funded work addresses the downstream consequences of progressive hepatic fibrosis, including structural changes that contribute to gastroesophageal bleeding risk and other complications of cirrhosis.

  • Hepatic fibrosis
  • Cirrhosis complications
  • Bleeding risk

Clinical interest extends to disease states where liver scarring alters vascular flow and increases the likelihood of variceal formation.

Metabolic Liver Disease

The trial portfolio reflects involvement in metabolic-associated liver disease, particularly NASH, where inflammation and fat-related injury progress to cirrhosis and related gastrointestinal complications.

  • Nonalcoholic steatohepatitis
  • Metabolic-associated liver disease
  • Cirrhotic progression

This area links liver injury from metabolic dysfunction with the management of advanced portal system complications.

Gastroenterology

Clinical interest includes upper gastrointestinal complications of cirrhosis, with emphasis on preventing the emergence of esophageal varices that can lead to serious bleeding events.

  • Upper gastrointestinal complications
  • Variceal prevention
  • Bleeding prevention

Research activity in this domain connects liver-centered disease with digestive tract outcomes that require ongoing surveillance and intervention.

Therapeutic Development in Fibrotic Liver Disease

The sponsor funds work around belapectin as a therapy of interest for cirrhosis associated with NASH, reflecting a focus on treatment options for advanced fibrotic liver disease and its vascular sequelae.

  • Belapectin
  • Fibrotic liver disease
  • Cirrhosis-related vascular complications

Its research landscape is concentrated on medical needs arising from chronic liver injury and the prevention of complications tied to portal circulation changes.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Belapectin for Preventing Esophageal Varices in Patients with NASH Cirrhosis

    Not recruiting

    4 1
    Belgium France Germany Poland Spain